肝癌新正子掃描製劑初報 New PET Agents for the Detection of HCC



Kai-Yuan Tzen, Director Department of Nuclear Medicine, National Taiwan University Hospital, 12/16/2009

Molecular characteristics of malignancy

- Proliferation
- Hypoxia
- Glycolysis
- Phospholipid synthesis
 - Fatty acid synthase
 - Choline metabolism
- Angiogenesis

- Receptor expression
- Transporter expression
- Antigen expression
- Apoptosis
- Gene delivery
- Multi-drug resistance



Time activity curve of different types of HCC in FDG accumulation



Acetate is a precursor of acetyl-CoA Experiment: 1-[¹⁴C]acetate is converted to 1-[¹⁴C]acetyl-CoA by cells

H₃C-¹⁴COO⁻ + CoASH <u>ATP</u> acetate thiokinase <u>AMP + PPi</u>

H₃C¹⁴C-SCoA



¹¹C-acetate vs. ¹⁸F-FDG scan



Hepatocellular Carcinoma (=< 3 lesions, size > 1.8 cm) **32 patients, 55** lesions

	Lesions	Percentage
¹¹ C-Acetate +ve ¹⁸ FDG -ve	29/55	52.7%
¹¹ C-Acetate + ¹⁸ FDG both positive	19/55	34.5%
¹¹ C-Acetate -ve ¹⁸ FDG +ve	7/55	12.7%
¹¹ C-Acetate -ve ¹⁸ FDG -ve	0/55	0.0%
Total ¹⁸ FDG positive (Sensitivity)	26/55	47.3%
Total ¹¹ C-Acetate positive (Sensitivity)	48/55	87.3%
Either ¹¹ C-Acetate or ¹⁸ FDG positive	55/55	100.0%

Choline

Eur J Nucl Med Mol Imaging (2006) 33:1285–1289

- An essential nutrient;
- Transported through choline transporter into cells;
- Phosphorylated to phosphoryl choline by choline kinase;
- Trapped into phospholipid pool.
- Correlated with cellular membrane phospholipid synthesis rate indicating proliferation.

Choline metabolism in cancer

 Overexpression of choline kinase in multiple tumor cell lines;

 Choline kinase increased in breast ca, colon ca.

Lipid metabolism in cancer cells



 Overexpression of fatty acid synthase (FAS);

 Overexpression of choline kinase (ChoK)



18F-Choline was synthesized in two steps as reported with some modifications (scheme 1)



Appl Rad and Isot 57 347-352, 2002



Procedure 1

- The recovered [¹⁸F]fluoride was passed through QMA.
- The eluent (vial 1) was used for elution of the absorbed fluoride.
- The reactor was then heated (110°C) for 2.5 mins and the solvent evaporated to dryness.
- The residue was dried by azeotropic evaporation with dry ACN (vial 2) to ensure complete removal of water.

Procedure 2

- Temperature of reactor was set to 65 $^\circ\!\mathrm{C}$.
- CH₂Br₂ in dry ACN (vial 3) was then added to reactor.
- During reaction the unreacted CH_2Br_2 and product ($CH_2Br^{18}F$) were vented to three silica cartridges connected in series.
- CH₂Br¹⁸F was delivered to the dry tC18 cartridge which was loaded with DMAE.



- After the reaction, the tC18 cartridge was washed with ethanol (vial 7) followed by water (vial 8).
- The final procuct, [¹⁸F]fluorocholine retained by CM cartridge (connected to tC18 cartridge) was then eluted with saline (vial 9).



X: Br or OTf

- 外觀:最終產物在經由無菌過濾膜過濾後,其狀況以目視法觀察必須透明無顆粒狀態的。
- 酸鹼度:以pH試紙測標準值在4.0-8.0之範圍。
- 放射性核種半衰期:以γ射線偵檢儀測標準值在110 ±5 min.之
 範圍。
- 放射化學純度與放射化學鑒別:用薄層層析法(TLC)以 aluminium sheets Silica gel置於展開液(乙月青:水 (95:5))中展開。以γ射線偵檢儀測放射化學鑒別R_f值 0.3 0.5,單一峰;放射化學純度標準值 > 90%。
- Radionuclidic purity:以多頻分析儀(Multi-channel analyzer)測標準值 > 99.5%在0.511MeV and/or 1.022MeV。
- Kryptofix 2.2.2 : 用TLC测標準值< 50 µg/ml。

- 殘餘溶劑:以氣相層析儀測DMAE < 0.1 mg /ml , Ethanol < 0.5%(w/v), Acetonitrile < 0.04%(w/v)。</p>
- 內毒素試驗:以動力比色儀(Kinetic Quantitative Chromogenic LAL Test) 測標準值< 175EU/V(≦5EU/ml)。
- 無菌過濾膜:最終產物經無菌過濾膜過濾後,用氣體測試無菌過 濾膜起泡點,標準須>45psi。
- 無菌測試: 在72小時內操作,將最終產物各注入FTM (Fluid Thioglycollate Medium)、SCD (Soybean Casein Digest) 培養,14天後觀察必須為清澈不混濁。



Times	30
	(5 failure and 25 success)
Success rate of synthesis	83.3 %
EOB	2 %
Time duration	40 mins
Radiochemical purity	> 90 %





F-18 Choline in HCC research

- NTUH IRB passed on 8/29/2008
- NSC grant approved since 1/1/2009
- DOH approval on 4/21/2009
- 1st case enrolled on 7/17/2009
- Totally 9 cases enrolled till 11/25/2009

HCC FDG PET scan



HCC F-choline PET scan



HCC ¹⁸FCH (Lt.) vs. ¹⁸FDG (Rt.)





寄件人: Nguyen Cong Duc

標題: Nguyen Cong Duc - Cho Ray Hospital, Unit of PET-CT and Cyclotron.

日期: 2009年11月2日 上午02時48分30秒

收件人: Kai-Yuan Tzen(曾凱元) <tzenky@ntuh.gov.tw>

Dear Dr. Kai-Yuan Tzen,

At first, I would like to send my warmest regards to you and your colleagues.

I would like to introduce myself again. I, Nguyen Cong Duc, have been working at the Unit of PET-CT and Cyclotron, Cho ray Hospital, Ho Chi Minh City, Vietnam. Now I would like to write to you for your assistance:

Dr. Nguyen Truong Son, Director of Cho ray Hospital and Dr. Hoang Hoa Hai, Head of Department of Training and Scientific Research had visited your institution and they are interested in the production and applications of F-18 Choline. We desire to develop this new PET radiopharmaceutical in our hospital.

Therefore, I wo would like to radiopharmace the situation, th And I also would we are only prod Please send m I wish you and y Thank you ver Nguyen Cong D Vice Head, PET-CT and Cyclo CHO RAY Hospita 201 B Nguyen Chi VIETNAM. 12/1/2009 - 1/31/2010Telephone: +84-8-Fax: +84-Cell phone: +84 9

ion of F-18 Choline and I line and the other PET ease let me be informed u about my study. ▶

arch this year and at present

Thank You Very Much for Your Attention

